Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab

• Published in: Anticancer research Vol. 40; no. 4; pp. 2157 - 2163
• Main Authors: Simetić, Luka, Blažičević, Krešimir, Međugorac, Kata, Golčić, Marin, Herceg, Davorin
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.04.2020
• Subjects: Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers; Biomarkers, Tumor - analysis; Confidence intervals; Disease-Free Survival; Female; Humans; Immunotherapy; Lung Neoplasms - secondary; Lymphatic Metastasis; Male; Melanoma; Melanoma - drug therapy; Melanoma - metabolism; Melanoma - pathology; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Multivariate analysis; Pembrolizumab; S100 Proteins - analysis; Skin Neoplasms - drug therapy; Skin Neoplasms - metabolism; Skin Neoplasms - pathology; Survival; S100; pembrolizumab; melanoma; immunotherapy; Analysis of survival

There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear. We evaluated patients with metastatic melanoma treated with pembrolizuma...